Abstract
Nanoparticulate formulations have been valuable imaging tools in preclinical cardiovascular disease research. Nanocarriers' distinct properties are useful to carry out imaging with significant functional versatility, which is not achieved by traditional small-molecule agents. Various cardiovascular diseases (CVDs) require molecular and cellular mechanisms understanding, which will provide valuable insight towards theranostic (diagnostic and therapeutic) applications. Nanocarriers and radiolabeled nanoparticulate probes demonstrate their utility in several CVDs applications such as blood pool imaging and molecular imaging of ischemia, angiogenesis, atherosclerosis, and inflammation. Further, these emergent technologies need to address safety, toxicity and regulatory obligations for their clinical translation.
Keywords: Microbubble, Nanoparticles. Imaging, Quantum dots.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Drug Targets - Cardiovascular & Hematological Disorders
Current Medicinal Chemistry - Cardiovascular & Hematological Agents
Current Cardiology Reviews
Current Hypertension Reviews
Cardiovascular & Hematological Agents in Medicinal Chemistry
Cardiovascular & Hematological Disorders-Drug Targets
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents